BioMarin Pharmaceutical (BMRN) FDA Approvals - MarketBeat
4 days ago · BioMarin Pharmaceutical's Drugs in the FDA Approval Process This section highlights FDA-related milestones and …
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children …
May 18, 2026 · "We are disappointed that the significant increases in plasma PPi observed with BMN 401 did not translate into …
U.S. Food and Drug Administration Accepts BioMarin’s ... - BioSpace
Jul 13, 2026 · FDA PDUFA target action date of Feb. 28, 2027 SAN RAFAEL, Calif., July 13, 2026 /PRNewswire/ -- BioMarin …
BioMarin Pharmaceutical Inc. - News
Jul 13, 2026 · U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of …
BioMarin Pharmaceutical Inc. News and Press Releases | PR Newswire
May 20, 2026 · BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial …
BioMarin Pharmaceutical Inc.: Official Announcements - Stock Market …
Jul 13, 2026 · Find the latest press releases and official documents published by BioMarin Pharmaceutical Inc. on MarketScreener.
Press Releases | BioMarin
Access BioMarin's archive of press releases covering financial results, clinical trial updates, product approvals and more.
BMRN Press Releases Biomarin Pharmaceutical - MarketChameleon.com
May 5, 2026 · View the latest Biomarin Pharmaceutical (BMRN) company-issued press releases.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children …
SAN RAFAEL, Calif., May 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from …
BioMarin Pharmaceutical : Fourth Quarter 2025 Press Release
Feb 23, 2026 · BioMarin will host a conference call and webcast to discuss fourth quarter 2025 financial results today, Monday, …